Surgical Oncology
Volume 19, Issue 1 , Pages e11-e21 , March 2010

Herceptin and breast cancer: An overview for surgeons

  • N. Patani

      Affiliations

    • The London Breast Institute, The Princess Grace Hospital, London, England, UK
    • ,
  • K. Mokbel

      Affiliations

    • The London Breast Institute, The Princess Grace Hospital, London, England, UK
    • St. George's University, London, England, UK
    • Corresponding Author InformationCorresponding author. London Breast Institute, The Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, UK. Tel.: +44 (0)207 908 2040; fax: +44 (0)207 908 2275.

,Accepted 25 November 2008.

References 

  1. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys. 2004;58:932–940
  2. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000;103:57–75
  3. Pegram M, Slamon D. Biological rationale for HER2/neu (cerbB2) as a target for mono clonal antibody therapy. Semin Oncol. 2000;27(Suppl. 9):13–19
  4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182
  5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(Suppl. 2):1–13
  6. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008 Jun;132(6):1008–1015
  7. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129(2):263–273
  8. Vamesu S. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol. 2007;48(2):121–129
  9. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11(3):117–127
  10. Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest. 2008 Jul;26(6):545–552
  11. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285–4289
  12. Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51
  13. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006;94:259–267
  14. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–446
  15. Cooley S, Burns L, Repka T, Miller J. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol. 1999;27:1533–1541
  16. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279–280
  17. Lane HA, Motoyama A, Beuvink I, Hynes N. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol. 2001;12:21–22
  18. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem. 2003;278:23 441–23 450
  19. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255–263
  20. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, et al. Trastuzumab-mediated antibodydependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11:4898–4904
  21. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744–4749
  22. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347–1355
  23. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4132–4141
  24. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11(Suppl. 1):4–12
  25. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253–268
  26. Ocana A, Cruz JJ, Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol. 2006 Feb;29(1):90–95
  27. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, et al. Neo-adjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10;23(11):2460–2468
  28. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2 overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res. 2006;12(3 Pt 1):845–853
  29. Niu G, Bradford Carter W. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res. 2007;67(4):1487–1493
  30. Wen X-F, Yang G, Mao W, Thornton A, Liu J, Bast RC, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006;25:6986–6996
  31. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007 Jun;18(6):977–984
  32. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007 May 28;26(25):3637–3643
  33. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215
  34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal anti body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792
  35. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274
  36. Perez EA, Rowland KM, Suman VJ. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: an NCCTG randomized phase II trial. [abstr 216] Breast Cancer Res Treat. 2003;82:S47
  37. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzu mab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20(14):3106–3113
  38. Herceptin prescribing information. Available from: www.gene.com2006;[accessed 1.10.07]
  39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Available from: www.nccn.org/professionals/physician_gls/PDF/breast.pdf. [accessed 1.10.07].
  40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Docetaxel and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2- positive operative breast cancer. Combined analysis of NSABP-B-31 and NCCTGN9831. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13–17, 2005, Oral presentation during symposium, advances in monoclonal antibody therapy for breast cancer.
  41. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  42. Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(Suppl. 18):512
  43. Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis. Breast Cancer Res Treat. 2006;100(Suppl. 1):53
  44. Piccart-Gebhart MJ, The Breast International Group. Advances in monoclonal antibody therapy for breast cancer. HERA trial. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13–17, 2005.
  45. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36
  46. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820
  47. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007 Aug 8;7:153
  48. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106(11):2337–2344
  49. Burstein HJ, Harris LN, German R, Lester SC. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21(1):46–53
  50. Harris LN, Burstein HJ, German R. Preoperative trastuzumab and vinorelbine is highly active, well-tolerated regimen for HER2 3+/FISH+stage II/III breast cancer. [abstr 86] Proc Am Soc Clin Oncol. 2003;22:[abstract no. 86]
  51. Hurley J, Dolina P, Silva O. Neo-adjuvant herceptin/taxotere/cisplatin in the treat ment of locally advanced and inflammatory breast cancer. [abstr 196] Proc Am Soc Clin Oncol. 2002;21:[abstract no. 196]
  52. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A, et al. Neo-adjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003;4:348–353
  53. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D, et al. Dose-dense neo-adjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Breast Cancer Res Treat. 2003;82:S55
  54. Carey LA, Dees EC, Sawyer L. Response to trastuzumab given with paclitaxel immediately following 4AC as initial therapy for primary breast cancer. Proceedings of the 24th San Antonio breast cancer symposium; 2002.
  55. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neo-adjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–3685
  56. Gianni L, Semiglazov V, Manikhas GM, Eiermann W, Lluch A, Tjulandin S, et al. Neo-adjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumor and safety analysis. J Clin Oncol. 2007;25:18S;[abstract 532]
  57. Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neo-adjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol. 2008 Apr;66(1):31–41
  58. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063–1070
  59. Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al. Capecitabine vs. capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). J Clin Oncol. 2008;26(May 20 Suppl.):[abstr 1025]
  60. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221
  61. Theodoulou M, Campos SM, Batist G. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol. 2002;21:55a
  62. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–7826
  63. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2902
  64. Herceptin (Trastuzumab) package insert, HER2 package insert. Genetech, Inc., USFDA; January 2000;
  65. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, et al. Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Program and abstracts of the 28th annual San Antonio breast cancer symposium, San Antonio, Texas; 2005 [abstr 2038].
  66. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Jul 23;25:3859–3865
  67. Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008 May;109(2):231–239[Epub 2007 Jul 19]
  68. Rastogi P, Jeong J, Geyer CE. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)_paclitaxel (T) vs. AC_T with trastuzumab (H). J Clin Oncol. 2007;25(Suppl. 18):513
  69. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  70. Geyer CE, Bryant JL, Romond EH, Ewer MS, Keefe DL, Shannon RP, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. ACT with trastuzumab (H). J Clin Oncol. 2006;24(Suppl. 18):581
  71. Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G, et al. Effect of cardiac dysfunction on treatment out comes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004;5(4):293–298
  72. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592–1600[Erratum, Cancer 2003;97:1136.]
  73. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865–1878
  74. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008 May;21(Suppl. 2):S8–S15
  75. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53:374–381
  76. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651–3664
  77. Mass RD, Press M, Anderson S, Murphy M, Slamon D. Improved survival benefit from herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol. 2001;20:22a;[abstract]
  78. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17(7):1974–1982
  79. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing—national surgical adjuvant breast and bowel project experience. Natl Cancer Inst. 2002;94(11):852–854
  80. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2006;24:3032–3038
  81. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allr66ed DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18
  82. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145
  83. Early Breast Cancer Trialists Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
  84. Kaufman PA, Broadwater G, Lezon-Geyda K. CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2_ and HER2- metastatic breast cancer (MBC). J Clin Oncol. 2007;25(Suppl. 18):1009
  85. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008 Mar 27;358(13):1409–1411
  86. Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. J Clin Oncol. 2007;25:18S;[Abstr 511]
  87. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol. 2007 Nov;19(6):552–557
  88. Press MF, Bernstein L, Sauter G, Zhou JY, Eiermann W, Pienkowski T, et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracyline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. [abstract no. 1045] Breast Cancer Res Treat. 2005;94(Suppl. 1):S54
  89. Kim C, Bryant J, Horne Z, Geyer CE, Wickerham DL, Wolmark N, et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo. Cancer Cell. 2004;5(4):317–328
  90. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361
  91. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, et al. Amplification and deletion of topoisomerase I alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156(3):839–847
  92. Munshi A, Singh P, Jalali R. Trastuzumab: is the new evidence revolutionary?. J Cancer Res Ther. 2006 Jul-Sep;2(3):144–146
  93. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 2000;355:1757–1770
  94. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2006;366:2087–2106
  95. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–453
  96. Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group Phase III trial N9831, 24; 2006, p. 523.
  97. Bendell J, Domchek S, Burstein H, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–2977
  98. Clayton A, Danson S, Jolly S, Ryder W, Burt P, Stewart A, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639–643
  99. Lin N, Bellon J, Winer E. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–3617
  100. Pestalozzi B, Brignoli S. Traztuzumab in CSF. J Clin Oncol. 2000;18:2350–2351
  101. Pal SK, Pegram M. HER2 targeted therapy in breast cancer beyond herceptin. Rev Endocr Metab Disord. 2007 Sep;8(3):269–277

PII: S0960-7404(08)00105-9

doi: 10.1016/j.suronc.2008.11.001

Surgical Oncology
Volume 19, Issue 1 , Pages e11-e21 , March 2010

Article Tools